Alessandra Tedeschi Selected Research

ibrutinib

10/2022	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
8/2022	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
6/2022	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.
5/2022	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
1/2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
1/2022	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
1/2022	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
1/2022	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
1/2022	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
1/2022	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandra Tedeschi Research Topics

Disease

60	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 03/2002
24	Waldenstrom Macroglobulinemia (Macroglobulinemia) 08/2022 - 03/2009
21	Neoplasms (Cancer) 01/2022 - 07/2002
13	Lymphoma (Lymphomas) 03/2022 - 09/2006
8	Residual Neoplasm 01/2022 - 07/2002
8	Atrial Fibrillation 01/2022 - 10/2017
8	Infections 06/2021 - 07/2002
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 08/2002
7	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 04/2019 - 07/2007
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2022 - 03/2004
5	Paraproteinemias (Monoclonal Gammopathy) 03/2022 - 02/2011
5	Diarrhea 01/2022 - 12/2015
5	Hypertension (High Blood Pressure) 01/2022 - 06/2018
5	Neutropenia 12/2021 - 03/2004
4	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 09/2006
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 04/2010
4	Disease Progression 01/2022 - 12/2011
4	Hemorrhage 12/2020 - 12/2015
3	Philadelphia Chromosome 01/2022 - 03/2006
3	Pneumonia (Pneumonitis) 01/2022 - 07/2002
3	B-Cell Lymphoma (Lymphoma, B Cell) 04/2021 - 06/2018
3	Anemia 02/2017 - 03/2002
2	Peripheral Nervous System Diseases (PNS Diseases) 03/2022 - 11/2013
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 03/2022 - 08/2020
2	Tumor Lysis Syndrome 01/2022 - 12/2021
2	Splenomegaly 11/2019 - 03/2002
2	Monoclonal Gammopathy of Undetermined Significance 04/2019 - 04/2013
2	Multiple Myeloma 04/2019 - 03/2016
2	Arthralgia (Joint Pain) 06/2018 - 07/2007
2	Nausea 06/2018 - 12/2015
2	Fatigue 01/2018 - 12/2015
2	Leukemia 09/2006 - 03/2002
1	Erythema 01/2022
1	Exanthema (Rash) 01/2022
1	Fever (Fevers) 01/2022
1	COVID-19 01/2022
1	Asthenia 01/2022
1	Sepsis (Septicemia) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 06/2021
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2021
1	Spasm (Spasms) 10/2020
1	Edema (Dropsy) 10/2020
1	Contusions 10/2020
1	Lymphadenopathy 11/2019
1	POEMS Syndrome (Syndrome, POEMS) 04/2019
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 04/2019
1	Amyloidosis 04/2019
1	Castleman Disease (Castleman's Disease) 04/2019

Drug/Important Bio-Agent (IBA)

40	ibrutinibIBA 10/2022 - 12/2015
19	Rituximab (Mabthera)FDA Link 03/2022 - 03/2004
17	fludarabineIBA 11/2020 - 07/2002
12	Agammaglobulinaemia Tyrosine KinaseIBA 10/2022 - 10/2017
12	Chlorambucil (Leukeran)FDA Link 01/2022 - 12/2015
10	zanubrutinibIBA 01/2022 - 09/2018
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2020 - 01/2003
8	Bendamustine Hydrochloride FDA Link 01/2022 - 04/2010
8	Immunoglobulin M (IgM)IBA 04/2021 - 02/2011
8	Alemtuzumab (Campath)FDA Link 01/2015 - 07/2002
6	obinutuzumabIBA 03/2022 - 01/2019
6	ofatumumab FDA Link 11/2020 - 01/2015
5	Biological ProductsIBA 01/2020 - 12/2011
5	Pharmaceutical PreparationsIBA 01/2019 - 04/2010
4	Monoclonal AntibodiesIBA 08/2016 - 07/2002
3	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2007
3	Alkylating AgentsIBA 06/2013 - 03/2009
2	ParaproteinsIBA 03/2022 - 11/2019
2	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2021
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2016
2	SteroidsIBA 01/2022 - 01/2021
2	venetoclaxIBA 01/2022 - 12/2021
2	duvelisibIBA 08/2020 - 07/2019
2	Staphylococcal Protein A (Protein A)IBA 11/2019 - 01/2017
2	6-bromo-2-naphthyl sulfate (BNS)IBA 01/2019 - 03/2016
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 01/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019 - 11/2015
2	Dihydrotachysterol (AT 10)IBA 06/2017 - 12/2013
2	Bortezomib (Velcade)FDA Link 01/2017 - 11/2013
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2017 - 11/2013
2	Immunoglobulins (Immunoglobulin)IBA 02/2011 - 07/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2011 - 09/2006
2	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2009 - 05/2007
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2009 - 05/2007
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 08/2009 - 05/2007
2	purineIBA 03/2009 - 02/2009
1	GalliumIBA 03/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	ponatinibIBA 01/2022
1	Dasatinib (BMS 354825)FDA Link 01/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 12/2020
1	InterferonsIBA 04/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Protein Subunit VaccinesIBA 01/2019
1	AntibodiesIBA 01/2019

Therapy/Procedure

30	Therapeutics 03/2022 - 03/2002
10	Drug Therapy (Chemotherapy) 03/2022 - 03/2002
4	Salvage Therapy 07/2019 - 04/2013
3	Immunotherapy 01/2019 - 07/2016
2	Stem Cell Transplantation 01/2018 - 03/2004
1	Drug Tapering 01/2022
1	Homologous Transplantation 01/2021